Joy Goudie Net Worth

The estimated Net Worth of Joy S. Goudie is at least $2.74 Thousand dollars as of 24 May 2023. Ms. Goudie owns over 300 units of Daxor stock worth over $2,742 and over the last 4 years she sold DXR stock worth over $0. In addition, she makes $0 as Independent Director at Daxor.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Ms. Goudie DXR stock SEC Form 4 insiders trading

Joy has made over 1 trades of the Daxor stock since 2023, according to the Form 4 filled with the SEC. Most recently she bought 300 units of DXR stock worth $2,925 on 24 May 2023.

The largest trade she's ever made was buying 300 units of Daxor stock on 24 May 2023 worth over $2,925. On average, Joy trades about 50 units every 0 days since 2020. As of 24 May 2023 she still owns at least 300 units of Daxor stock.

You can see the complete history of Ms. Goudie stock trades at the bottom of the page.

Joy Goudie biography

Joy Goudie Esq. serves as Independent Director of the Company. Joy Goudie, Esq. is currently a partner at Wissing Miller, LLP, following twelve years as Senior Patent Counsel for Revlon leading cross-functional teams in the US and Spain. In addition, she served as Vice President managing Revlon’s global R&D portfolio and driving new technologies. A published scientist, Ms. Goudie has worked with patents and R&D teams in the development of new antibiotics and small molecules for treatment of solid tumor cancers.

What's Joy Goudie's mailing address?

Joy's mailing address filed with the SEC is 109 MECO LANE, , OAK RIDGE,, TN, 37830.

Insiders trading at Daxor

Over the last 21 years, insiders at Daxor have traded over $7,541,627 worth of Daxor stock and bought 473,408 units worth $2,888,339 . The most active insiders traders include Joseph Feldschuh, Bruce Slovin, and Robert J Michel. On average, Daxor executives and independent directors trade stock every 39 days with the average trade being worth of $27,740. The most recent stock trade was executed by Robert J Michel on 27 March 2024, trading 750 units of DXR stock currently worth $6,525.

What does Daxor do?

the bva-100 (blood volume analyzer) is the first instrument of its kind that can precisely measure the amount of blood a patient has in their body. blood volume measurements have been available for almost 60 years, but the test often took 4 to 8 hours to perform and was very difficult to perform accurately. due to these issues, blood volume measurements were very rarely done. physicians had been forced to rely on substitute tests that were only able to measure the thickness of the blood and can be very misleading in many surgical and medical situations. the bva-100 can measure blood volume: accurately, quickly & reliably.

Complete history of Ms. Goudie stock trades at Daxor

Daxor executives and stock owners

Daxor executives and other stock owners filed with the SEC include:

• Jonathan Adam Feldschuh,
  Chief Scientific Officer & Director
• Michael Richard Feldschuh,
  Chairman, Pres & CEO
• Diane Meegan,
  IR Contact Officer
• Robert Willens,
  Independent Director
• James Lombard,
  Independent Director
• Joy Goudie,
  Independent Director
• Edward Feuer,
  Director
• Henry Cremisi,
  Director
• Jonathan Feldschuh,
  Chief Scientific Officer, Director
• Robert Michel,
  Chief Financial Officer
• Michael Feldschuh,
  Chairman of the Board, President, Chief Executive Officer
• Robert J. Michel M.B.A., CPA, CPA,
  CFO, Chief Compliance Officer & Corp. Sec.
• Guido Manzo,
  VP of Sales
• Kathryn A. Kornafel,
  VP of Marketing & Commercial Devel.
• Robert J. Michel M.B.A., C.P.A., CPA,
  CFO, Chief Compliance Officer & Corp. Sec.
• Caleb Des Rosiers,
  Director
• Of Joseph Feldschuh Estate,
  10% owner
• Bernhard Saxe,
  Director
• Soren Thompson,
  VP, Business Development
• Everis Engstrom,
  Vice President
• Robert G Moussa,
  Director
• Martin S Wolpoff,
  Director
• Philip Nordan Hudson,
  Director
• Joseph Feldschuh,
  President & CEO
• Stephen Valentine,
  Director
• Bruce Slovin,
  Director
• Gary Joseph Fischman,
  President